2024-11-18 06:45:09
Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting
Corporate/ 2023-07-24
Innovent Announces Phase 1 Clinical Data...

ROCKVILLE,Md. and SUZHOU,China,June 12,2023-- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical c...

Taipei Entrepreneurs Hub Focuses on the Greater Health Industries, Taipei City Government Facilitates Global Talents Matchmaking
Health/ 2023-07-22
Taipei Entrepreneurs Hub Focuses on the ...

TAIPEI,June 12,2023-- The Taipei City Government continues to promote the "Talent Exchange Program" in support of international en...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release